Global Onychomycosis Market Scope 2024, Forecast To 2033
8 Mar, 2024
The onychomycosis market has shown robust growth, increasing from $3.4 billion in 2023 to $3.61 billion in 2024, with a compound annual growth rate (CAGR) of 6.1%. This growth is attributed to factors such as limited treatment options and the aging population. Looking forward, the market is expected to continue its strong growth, reaching $4.45 billion by 2028, with a CAGR of 5.4%. Emerging trends such as integration of digital technologies in diagnosis and management are expected to drive this growth, alongside major trends including advancements in topical drug formulations and rise in over-the-counter antifungal products.
Global Onychomycosis Market Key Driver
The rise in diabetic patient population is expected to drive growth in the onychomycosis market. With millions affected by diabetes, foot complications like onychomycosis are on the rise. Data from the International Diabetes Federation underscores the significant global impact of diabetes, highlighting the need for effective treatment solutions. Therefore, the increasing incidence of diabetes fuels the growth of the onychomycosis market.
Get A Free Sample Of The Global Onychomycosis Market ReportGlobal Onychomycosis Market Segments
The onychomycosis market covered in this report is segmented –
1) Type:Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis, Other Types
2) Treatment:Drug Treatment, Topical Therapy, Other Treatments
3) Distribution Channel:Hospitals Pharmacies, Retail Pharmacies, Other Distribution Channels
By Geography: The countries covered in the onychomycosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the onychomycosis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Onychomycosis Industry Players
Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co. Inc.; Bayer AG; Novartis AG; GlaxoSmithKline PLC; Eli Lilly and Company; Sandoz International GmbH; Bausch Health Companies Inc.; Perrigo Company plc; Galderma Laboratories LP; Aurobindo Pharma Limited; Cipla Inc.; Dr.Reddy's Laboratories Ltd.; Apotex Inc; Lupin Limited; Amneal Pharmaceuticals Inc.; Alembic Pharmaceuticals Inc.; Kaken Pharmaceutical Co. Ltd.; Mayne Pharma Group Limited; Wockhardt Ltd.; Sato Pharmaceutical Co. Ltd.; Anacor Pharmaceuticals Inc.; Jubilant Cadista Pharmaceuticals Inc.; Moberg Pharma AB; Medimetriks Pharmaceuticals Inc.; Blueberry Therapeutics Ltd.; Hallux Inc.; NovaBiotics Ltd.; Zydus Cadila Healthcare Limited.
Get The Full Global Onychomycosis Market ReportOnychomycosis Market Overview
Onychomycosis is a nail infection that can affect the matrix, bed, or plate of the nail, as well as the toenail or fingernail. It is a typical condition brought on by different fungi, such as dermatophytes, yeasts, and molds.